Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck

Clavel, M.; Vermorken, Jan B.; Cognetti, F.; Cappelaere, P; Mulder, P.H.M. de; Schornagel, J. H.; Tueni, Elias; Verweij, Jaap; Wildiers, J.; Clerico, Mario; Dalesio, Otilia; Kirkpatrick, A.; Snow, Gordon B.

doi:10.1093/oxfordjournals.annonc.a058906

Cited by 251 publications

(113 citation statements)

References 13 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Although 20 -30% of patients may survive for 2 years, moderate to severe complications (including carotid blow-out) have been reported in 30 -40% of cases. Chemotherapy for these recurrent cancers has a response rate of no more than 10 -30% with a median survival of about 6 months (Clavel et al, 1994). Newer drugs have not improved the response rates significantly from those seen with traditional cisplatin-based chemotherapy (Forastiere et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer

et al. 2004

View full text Add to dashboard Cite

Interstitial photodynamic therapy (IPDT) is a technique for applying photodynamic therapy (PDT) to internal tumours using light delivered via fibres inserted percutaneously. This phase I -II study assessed the safety and efficacy of IPDT for patients with persistent or recurrent head and neck cancer unsuitable for further treatment with surgery, radiotherapy or chemotherapy, recruited for 'last hope' salvage treatment. Patients were sensitised with 0.15 mg kg À1 mTHPC (meso-tetrahydroxyphenyl chlorin) 4 days prior to light delivery from fibres inserted directly into the target tumour (20 J per site at 652 nm) under image guidance. In all, 45 patients were treated. Nine achieved a complete response. Five are alive and free of disease 10 -60 months later. Symptomatic relief (mainly for bleeding, pain or tumour debulking) was achieved in a further 24. The median survival (Kaplan -Meier) was 16 months for the 33 responders, but only 2 months for the 12 nonresponders. The only serious complication was a carotid blow out 2 weeks after PDT. No loss of function was detected in nerves encased by treated tumours. Interstitial photodynamic therapy provides worthwhile palliation with few complications and occasional long-term survivors for otherwise untreatable advanced head and neck cancers. It is a treatment option worth adding to those available to integrated head and neck oncology teams.

show abstract

Section: Discussionmentioning

confidence: 99%

Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Last received: August 2, 2007 Accepted: January 4,2008 REFERENCES recurrent or metastatic head and neck cancer ranges from 15 to 30%, depending on performance status, previous treatments and tumor burden. 16 With the use of polychemotherapy, the response rates increase to 20 to 35%, although without significant improvement in survival.…”

Section: Conflict Of Interest: Nonementioning

confidence: 99%

“…1 The most frequently used chemotherapy regimen includes four to five days continuous infusion of 5-fluorouracil and bolus cisplatin. [2][3][4][5] In our country, the expense of pumps for continuous outpatient chemotherapy infusion, together with the scarcity of beds for elective admissions for palliative chemotherapy in an inpatient setting, prompted us to develop a protocol that could be administered without the need for hospital admission.…”

Section: Introductionmentioning

confidence: 99%

Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas

2008

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: Patients with advanced head and neck (H/N) and esophageal squamous cell carcinoma (SCC) often have a poor performance status and a dire prognosis. Our aim was to evaluate the feasibility, activity and quality of life (QOL) of an outpatient chemotherapy regimen consisting of cisplatin, 5-fluorouracil and leucovorin (CFL). DESIGN AND SETTING:Prospective phase II study conducted at a Brazilian public institution.

show abstract

“…Five year overall survival rates for unresectable recurrent or metastatic (R/M) head and neck squamous cell carcinoma (R/M HNSCC) are poor and there are few effective treatment options although platinum based chemotherapy remains the standard [1][2][3]. To date the best median overall survival is seen with combination of a platinum agent, 5-flourouracil and cetuximab, but the toxicity of this treatment limits its use [4].…”

Section: Introductionmentioning

confidence: 99%

Alternative Imaging Response Criteria with the Use of Axitinib in Head and Neck Cancer: An Exploratory Analysis Utilizing the Choi Criteria

Swiecicki¹,

Dickerson²,

Bell³

et al. 2017

Otolaryngol

View full text Add to dashboard Cite

Objective: The purpose of this study was to explore the utility of the Choi Criteria in judging response to axitinib therapy in unresectable recurrent or distant metastatic head and neck squamous cell carcinoma.Methods: Radiologic and clinical data was evaluated in a retrospective fashion from a single-arm phase II clinical trial of axitinib for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma. Twenty-nine patients had imaging to which the Choi Criteria were applied in an exploratory fashion. Responses rates by Choi Criteria were compared to those identified by RECIST v1.0 and statistical analyses were performed to evaluate significance. Association of best response to survival was also examined for each criteria (RECIST v1.0 and Choi). Results:Application of the Choi Criteria demonstrated that 65.5% of patients achieved a partial response versus 6.9% by RECIST v1.0. Disease control rate was identical by Choi Criteria and RECIST v1.0 at 72.4%. Response to therapy based on Choi Criteria correlated to significantly improved estimated overall survival at 12 months (63% vs. 20%, p=0.03), whereas response to therapy based on RECIST was not a significant predictor of survival. Conclusion:The Choi Criteria appear to better identify patients responding to therapy with the anti-angiogenic tyrosine kinase inhibitor axitinib versus RECIST v1.0 in this exploratory analysis. Use of the Choi Criteria to guide treatment decisions in further studies utilizing axitinib in this population may better identify patients benefiting from therapy.

show abstract

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck

Abstract: We conclude that the CF regimen has no advantage over the CABO regimen, which in fact showed a higher complete response rate. Both combinations showed improved response rates but also more toxicity and no improvement in overall survival in comparison with cisplatin alone.

Cited by 251 publications

References 13 publications

Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer

Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer

Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas

Alternative Imaging Response Criteria with the Use of Axitinib in Head and Neck Cancer: An Exploratory Analysis Utilizing the Choi Criteria

Contact Info

Product

Resources

About